The global bioelectronic medicine market was valued at $8.9 billion in 2025 and is projected to reach $21.6 billion by 2034, according to a ResearchAndMarkets.com report covering market dynamics, technologies, applications, companies and regional opportunities from 2023 through 2034. Bioelectronic medicine uses implantable and non-invasive devices to deliver targeted electrical stimulation to peripheral nerves, the spinal cord or the brain, modulating neural circuits as an alternative or complement to pharmaceutical treatment. The report examines spinal cord, deep brain, sacral and tibial, vagus nerve, responsive and closed-loop, hypoglossal nerve, peripheral and non-invasive stimulation systems. Applications include chronic pain, movement disorders, urinary and bowel dysfunction, obstructive sleep apnea, epilepsy, depression and psychiatric disorders, and inflammatory and autoimmune diseases. North America held the largest regional share in 2025, while Asia-Pacific is expected to show strong future development as healthcare infrastructure and adoption of advanced medical technologies expand. The competitive landscape includes Medtronic, Boston Scientific, Abbott, Nevro, LivaNova, Axonics, SetPoint Medical, Galvani Bioelectronics, NeuroPace, Inspire Medical Systems, electroCore and Saluda Medical.